Abstract 1960P
Background
Bone and soft tissue sarcomas are uncommon neoplasms that rarely metastasize to the brain. Alveolar soft tissue sarcomas (ASPS) have been reported to have a higher propensity to develop brain metastasis (BM) than other sarcomas. Our study aimed to retrospectively scrutinize the clinical outcome of BM in ASPS.
Methods
35 patients diagnosed with ASPS between 2006 and 2021 were identified from our database. We evaluated the presence or absence of BM, age at diagnosis, gender, primary lesion site, tumor size, other distant metastases at diagnosis, and prognosis. We compared these clinical characteristics between patients with BM and those without BM (nBM). In the BM group, we also assessed symptoms, duration between diagnosis and BM, treatment for BM, and outcomes.
Results
Fifteen patients (43%) exhibited BM. We observed no significant difference in age at diagnosis, gender, primary lesion site, tumor size, or other distant metastases at diagnosis or median overall survival, compared to the nBM group. Seven cases were asymptomatic when BM was diagnosed. Most symptoms were headache and visual disturbance. The mean duration between diagnosis and BM was 46 months (range: 0-189). BM treatment consisted of gamma-knife radiosurgery in 10 cases, multi-targeted kinase inhibitors (TKI) (pazopanib and/or sunitinib) in eight cases, surgery in three cases, and whole-brain irradiation in three cases. After receiving sunitinib treatment, two patients developed brain hemorrhages. The survival after BM was 33 months (range: 0.5-104).
Conclusions
Approximately half of the ASPS cases included in our study developed BM, with 47% of ASPS patients being asymptomatic at the time of BM detection. Periodic imaging, including the head region, may be advisable. Our analysis did not identify specific clinical features that predict BM in ASPS patients. Selective irradiation and chemotherapy have recently emerged as potential therapeutic options for treating BM in ASPS. These advances may contribute to improved prognosis after BM. However, potential serious adverse events associated with these treatments should be carefully considered. In particular, patients receiving TKI therapy may be at risk for brain hemorrhages and should be closely monitored and managed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
E. Kobayashi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1949P - Pegylated liposomal doxorubicin (PLD) combined with trabectedin as a treatment option in uterine sarcomas
Presenter: Laura Strobel
Session: Poster session 15
1950P - A single-arm, phase II clinical trial of neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma
Presenter: Yong Chen
Session: Poster session 15
1951P - Propranolol monotherapy in angiosarcoma: A window-of-opportunity study (PropAngio)
Presenter: Alaa Embaby
Session: Poster session 15
1952P - Efficacy and safety of utidelone in previously treated patients with advanced or metastatic soft tissue sarcomas (HX-SARC02): A prospective, single-arm, phase II study
Presenter: yu jiang
Session: Poster session 15
1953P - Prognostic value of pretreatment inflammatory markers and other clinicopathological factors for early recurrence in soft tissue sarcoma
Presenter: Pia Van Der Laan
Session: Poster session 15
1954P - The risk of second primary gastrointestinal tract GIT malignancy after primary retroperitoneal liposarcoma
Presenter: Bushra Alshaikh
Session: Poster session 15
1955P - Distinguishing lipomas from atypical lipomatous tumors/well differentiated liposarcomas in histology slides using deep learning
Presenter: Marie karanian
Session: Poster session 15
1956P - Neoadjuvant chemoradiotherapy in locally advanced soft tissue sarcoma: NASAR prospective study
Presenter: Jeronimo Martinez-Garcia
Session: Poster session 15
1957P - Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)
Presenter: Rashmi Chugh
Session: Poster session 15
1958P - Head and neck soft tissue sarcoma: Evaluation of the 8th AJCC as a prognostic tool for patients treated with curative intent in a multidisciplinary cancer center
Presenter: Giulia Zanetta
Session: Poster session 15